Journals / Medicine Science / 2020 / Cilt: 9 - Sayı: 2

Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance

Pages
496–502
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Immunohistochemical methods have very important progression in diagnosis of cancer, its origin and subtypes and however IHC also could have a key role in treatment of cancer by targeted therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study is to determine the correlation of histopathological subtype with frozen section examination and the importance of immunohistochemical analysis of ovarian malignancies which also include metastatic ones.
📊
Key Findings & Data:This study is a retrospective study that have included 55 patients who have been operated for adnexial tumor and have the diagnosis of malignancy during surgery by frozen section or after surgery by final pathologic examination done by immunohistochemistry (IHC).
💡
Conclusion & Impact:Immunohistochemical methods have very important progression in diagnosis of cancer, its origin and subtypes and however IHC also could have a key role in treatment of cancer by targeted therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

The aim of this study is to determine the correlation of histopathological subtype with frozen section examination and the importance of immunohistochemical analysis of ovarian malignancies which also include metastatic ones. This study is a retrospective study that have included 55 patients who have been operated for adnexial tumor and have the diagnosis of malignancy during surgery by frozen section or after surgery by final pathologic examination done by immunohistochemistry (IHC). The mean age of the patients with malignant ovarian tumor is 52.33 ± 15.5 years. When the pathologic diagnosis reports examined it has been found that 34 of 55 patients (61.8 %) have had epithelial type, 9 have had sex cord stromal tumor, 3 have had germ cell type and 9 of the patients have had metastatic ovarian cancer. Survival rates have been found as 70.6 % for epithelial ovarian cancer, 100 % for sex cord stromal tumors, 100 % for germ cell tumor and 44.4 % for metastatic tumors. Despite the rapid development in examination and imaging methods, histopathology is the pivotal issue in the diagnosis and also in sub-type diagnosis of pelvic mass lesions. The improvement is better in patients evaluated and operated in gynecologic oncology centers. The two important factor in this subject is the experience of the surgeon for maximum salvage from the tumoral burden and the well examination by frozen section the immunohistochemical methods for the discrimination of gastrointestinal tumors which can mimic ovarian primary tumors. Immunohistochemical methods have very important progression in diagnosis of cancer, its origin and subtypes and however IHC also could have a key role in treatment of cancer by targeted therapy.

🔖

Cite This Article

BALOĞLU, D., ÇOŞKUN, E. İ., ALAN, S., YILMAZ, E., KUTLUTÜRK, K. (2020). Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance. Medicine Science, Cilt: 9 - Sayı: 2, 496–502. https://ajindex.com/articles/276890

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Globocan (2012), Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2018:
  2. T.C. Sağlık Bakanlığı. Türkiye Halk Sağlığı Genel Müdürlüğü. Kanser Dairesi Başkanlığı. Türkiye Kanser İstatistikleri: https://hsgm.saglik.gov.tr/ tr/kanser-istatistikleri 3. National Cancer Institute: SEER Cancer Statistics Review (CSR) 1975– 2014.
  3. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7–30
  4. Goodman MT, Shvetsov YB. ‘ Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United states, 1995-2004’. Cancer epidemiol Biomarkers Prev. 2009;18:132-9
  5. Vencken PM, Kriege M, Hoogwerf D, et al. ‘Chemosensitivity and outcome of BRCA1 and BRCA2 associated ovarian cancer patients after first line chemotherapy compared with sporadic ovarian cancer patients’ Ann Oncol. 2011;22:1346-52
  6. Purdie DM, Bain CJ, siskind V, et al. Ovulation and risk of epithelial ovarian cancer. Int J Cancer. 2003;104:228-32
  7. Berek SJ, Berek and Novak’s Gynecology. 2007. p. 1457-9
  8. Seidman JD, Russel P, Kurman RJ (2002). Surface epithelial tumours of the ovary. In: Kurman RJ (edn): Blaustein’s Pathology of the female genital tract, (5 th edn), Springer-Verlag, New York
  9. Kurman RJ, Shih I. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory, Am J surg Pathol. 2010;34:433-43
  10. Chen VW, ruiz B, Kılleen JL, et al. Pathology and classification of ovarian tumors. Cancer. 2003;15(10 suppl):2631-42
  11. Schumer ST, Cannistra SA. ‘Granulosa cell tumor of the ovary’,J clin Oncol. 2003;21:1180-9
  12. Talerman A, Path FRC.(2002), Germ cell tumors of the ovary. In Kurman R (ed): Blaustein’ s Pathology of the Female Genital Tract, 5 th ed. New York, Springer-Verlag, p. 967-1034
  13. Turan T, Aykan B, Koç S, et al. Analysis of metastatic ovarian tumors from extra-genital primary site. Tumori. 2006;92:493-7
  14. Moore RG, Chung M, Granai GO, et al. Incidence of metastasis to the ovaries from nongenital tract tumors. Gynecol Oncol. 2004;93: 87-91
  15. Ümmugul Ü, Arslan ŞH, et al. Isolated ovarian metastasis of gastric cancer. Krukenberg Tumor Contemp Oncol (Pozn). 2013;17:515-9
  16. Asotra S, Sharma J, Sharma N. Metastatic ovarian tumor. J Cytol. 2009;26:144-5
  17. Di Saia, Creasman. Clinical Gynecologic Oncology 8th Ed. 2012;Chapter 12, p
  18. Elsevier Saunders 19. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovar